Related Experiment Video
Updated: Jul 19, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Development and validation of a hybrid deep learning-machine learning approach for severity assessment of COVID-19
Doohyun Park1, Ryoungwoo Jang2, Myung Jin Chung3,4
1School of Electrical and Electronic Engineering, Yonsei University, Seoul, Republic of Korea.
Abstract:
The Coronavirus Disease 2019 (COVID-19) is transitioning into the endemic phase. Nonetheless, it is crucial to remain mindful that pandemics related to infectious respiratory diseases (IRDs) can emerge unpredictably. Therefore, we aimed to develop and validate a severity assessment model for IRDs, including COVID-19, influenza, and novel influenza, using CT images on a multi-centre data set. Of the 805 COVID-19 patients collected from a single centre, 649 were used for training and 156 were used for internal validation (D1). Additionally, three external validation sets were obtained from 7 cohorts: 1138 patients with COVID-19 (D2), and 233 patients with influenza and novel influenza (D3). A hybrid model, referred to as Hybrid-DDM, was constructed by combining two deep learning models and a machine learning model. Across datasets D1, D2, and D3, the Hybrid-DDM exhibited significantly improved performance compared to the baseline model. The areas under the receiver operating curves (AUCs) were 0.830 versus 0.767 (p = 0.036) in D1, 0.801 versus 0.753 (p < 0.001) in D2, and 0.774 versus 0.668 (p < 0.001) in D3. This study indicates that the Hybrid-DDM model, trained using COVID-19 patient data, is effective and can also be applicable to patients with other types of viral pneumonia.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

